The Federal Government on Wednesday evening confirmed the receipt of a popular HIV prevention injection known as Lenacapavir.
The development, approved by the Coordinating Minister of Health and Social Welfare, Ali Pate, and supported through the Global Fund, represents a major advancement in the country’s HIV prevention efforts and further strengthens Nigeria’s commitment to expanding innovative HIV prevention options.
The introduction of Lenacapavir for pre-exposure prophylaxis marks a significant step toward broadening the range of prevention choices available to individuals at risk of HIV infection.
As a long-acting injectable option, LEN PrEP has the potential to improve adherence and expand access to effective HIV prevention services for populations that may face challenges with daily oral prevention options.
Announcing the arrival in a statement, the National Coordinator of the National HIV, Viral Hepatitis and STDs Control Programme at the Federal Ministry of Health and Social Welfare, Dr Adebobola Bashorun, said the Federal Government’s receipt of LEN PrEP reflects Nigeria’s continued dedication to leveraging innovation and evidence-based interventions to accelerate progress toward epidemic control.
By expanding prevention options and strengthening service delivery, he said the country was taking decisive steps to reduce new HIV infections and improve health outcomes for communities across Nigeria.
Bashorun said, “NASCP, in collaboration with partners and stakeholders, will work to ensure the safe introduction, strategic deployment, and effective integration of Lenacapavir into the national HIV prevention options. The rollout will support ongoing efforts to increase access to prevention services while reinforcing Nigeria’s broader HIV response.
“NASCP remains committed to advancing equitable access to HIV prevention, testing, treatment, and care services. The arrival of long-acting injectable Lenacapavir is a clear demonstration of Nigeria’s resolve to scale up innovative solutions and strengthen the fight against HIV.
“Together, Nigeria moves closer to ending HIV as a public health threat.”
Lenacapavir is an injectable treatment administered twice yearly, offering a more convenient alternative to daily oral preventive medications.
The drug is expected to be available in Nigeria and 119 other low- and middle-income countries at an affordable cost of $40 per person annually, following voluntary licensing agreements with generic manufacturers.
